Luxendo closes €6m series-A

With the fresh capital, the company plans to further develop its product, which is scheduled to go on sale in 2016. 

EMBL's Stefan Herr and LSP's Joachim Rothe will join Luxendo's board.

EMBL invests throughout Europe in life-science companies. The VC manages €68m on behalf of major European institutional and private investors and typically invests €3-5m as a lead or co-lead investor.

LSP offers seed, early-stage and late-stage financing to private and public life-science companies. It prefers to invest in small and mid-cap companies operating in healthcare and biotechnology sectors across Europe and the US.

Company
Founded in 2015 and based in Heidelberg, Luxendo is a spinout from the European Molecular Biology Laboratory (EMBL). Single-plane illumination microscopes combine optical sectioning with multiple-view imaging to observe tissues and living organisms in high resolution.

People
Stefan Herr is a partner at EMBL. Joachim Rothe is a partner at LSP. Lars Hufnagel led the team that developed the microscope.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany